Non-Hodgkin Lymphoma News

• IWMF 2019New Lymphoma Drugs Build on BTK Inhibitor Success Life expectancy for patients with Waldenstrom's macroglobulinemia has improved considerably in the past decade, and new treatments on the horizon could mean that trend continues.
  Medscape Medical News, May 2019
• IWMF 2019Patients With Rare Lymphoma Describe Divergent Experiences Some people are treated aggressively while others watch and wait until symptoms appear; three will describe their experiences at the upcoming Waldenstrom's Macroglobulinemia forum.
  Medscape Medical News, May 2019
• Cemiplimab and Talazoparib Head Toward Approval in the EU Both drugs have received a positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use, which is the first step in obtaining marketing approval in the European Union.
  International Approvals, April 2019
• Novel CAR T-Cell Approach Reduces Toxicities, Retains Efficacy The modified molecule for the anti-CD19 CAR T-cell therapy shows signs of reducing the risk for severe cytokine release syndrome while maintaining efficacy.
  Medscape Medical News, April 2019
• For Rare, Difficult Cancer, New Drug Is a 'Major Advance' Tagraxofusp, the first-ever drug for blastic plasmacytoid dendritic-cell neoplasm, is being called a major advance. Data are now published in the New England Journal of Medicine.
  Medscape Medical News, April 2019
• Pesticide Exposure Linked to Worse Outcomes in Diffuse Large B-Cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) patients exposed to pesticides on the job have worse overall survival (OS) and event-free survival (EFS) and are less likely to respond to treatment, according to new findings.
  Reuters Health Information, April 2019
• Promising Results in Mice Prompt Human Trial of Novel Lymphoma Vaccine An in situ vaccine (ISV) combined with immune stimulants and radiotherapy showed efficacy in mice, prompting a phase 1 trial of patients with advanced indolent non-Hodgkin's lymphoma (INHL), researchers say.
  Reuters Health Information, April 2019
• BSH 2019ITP and B-cell Lymphoma Feature in Latest BSH Guidance Recommendations on tackling osteoporosis in immune thrombocytopenia and mediastinal B-cell lymphoma management are the latest guidance by the British Society for Haematology in a prolific year.
  Medscape News UK, April 2019
• Health Canada Plans to Suspend Allergan's Breast Implant License Health Canada said on Thursday it was advising Allergan Plc of the regulator's plans to suspend the license for the Botox-maker's Biocell breast implants, after a review regarding the risk of a rare cancer linked to breast implants.
  Reuters Health Information, April 2019
• Umbralisib Shows Promise in Relapsed/Refractory Marginal Zone Lymphoma Umbralisib, an investigational oral inhibitor of PI3K-delta, has significant activity against relapsed/refractory marginal-zone lymphoma (MZL) and manageable side effects, according to early results from an ongoing phase 2b trial.
  Reuters Health Information, April 2019
• Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.
  Reuters Health Information, April 2019
• Rituximab Fails to Improve Symptoms in ME/CFS New findings in treating myalgic encephalomyselitis/chronic fatigue syndrome (ME/CFS) contradict previous observations and preliminary trial results; illness heterogeneity was cited as a research challenge.
  Medscape Medical News, April 2019
• U.S. Jury Says Bayer Must Pay $80 Mln to Man in Roundup Cancer Trial A U.S. jury on Wednesday awarded $80 million to a man who claimed his use of Bayer AG's glyphosate-based weed killer Roundup caused his cancer, in the latest legal setback for the company facing thousands of similar lawsuits.
  Reuters Health Information, March 2019
• More Info on Risks of Breast Implants Needed, Says FDA Panel A 2-day meeting highlighted the risk for a rare lymphoma, described as a 'man-made cancer,' and heard calls for a ban on certain products, but advisers also highlighted lack of data.
  Medscape Medical News, March 2019
• EBMT 2019Stem Cell Transplant Patients Face Lifelong Cancer Risk Patients undergoing hematopoietic stem cell transplant should be counseled that they have an ever-increasing risk for further malignancies, although their survival may not be affected, say experts.
  Medscape Medical News, March 2019
• Low-dose, Low-frequency PUVA May Be Suitable for Maintenance Therapy in Mycosis Fungoides In patients with early-stage mycosis fungoides, treatment and maintenance therapy with low-dose, low-frequency oral psoralen - UV-A (PUVA) may extend disease-free remission, a proof-of-concept study reveals.
  Reuters Health Information, March 2019
• NCCN 2019ER Doc Survives Cancer, Now Must Survive ER A Florida-based ER physician with an aggressive lymphoma underwent a 'miracle' treatment but now has a weakened immune system. Back at work, now he has to survive the ER and its germs.
  Medscape Medical News, March 2019
• Breast Implant ALCL: Excellent Prognosis if Treated Promptly Clinicians encouraged to follow 2019 NCCN guidelines, discuss risks, symptoms as part of patient consent for textured breast implants.
  Medscape Medical News, March 2019
• Long-Term Cancer Survivors at Higher Risk of Hospitalization for Other Diseases Survivors of the 12 most common cancers are at higher risk for a wide range of diseases that require hospitalization and should be monitored for new illnesses during follow-up visits, researchers say.
  Reuters Health Information, March 2019
• Better Lymphoma Outcomes With Bendamustine-Rituximab Combination The combination of bendamustine and rituximab provides better progression-free survival (PFS), event-free survival, and duration of response in patients with indolent non-Hodgkin lymphoma and mantle-cell lymphoma, compared with other regimens, according to five-year results from the BRIGHT follow-up study.
  Reuters Health Information, March 2019